Drug Profile
Agalsidase beta - Sanofi
Alternative Names: Fabrazyme; Recombinant human α-galactosidase A - SanofiLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genzyme Canada; Genzyme Corporation
- Developer Icahn School of Medicine at Mount Sinai; Sanofi
- Class Galactosidases; Glycoproteins; Isoenzymes; Recombinant proteins
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fabry's disease
Most Recent Events
- 31 Dec 2022 Sanofi has patent protection for pediatric indication with confirmed Fabry's disease, in USA, prior to December 2022
- 01 Oct 2021 Launched for Fabry's disease in China (IV), before October 2021 (NCT05054387) (NDR Batch 21)
- 12 Mar 2021 Efficacy data from a phase IV trial in Fabry's disease released by Sanofi Genzyme